PAX5 and acute lymphoblastic leukemia: Deletion of IKZF1 is associated with particularly poor clinical outcomes (Mullighan et al., 2009), and recent studies based on a PAX5 restoration model clearly validated the powerful tumor-suppressive function of PAX5 in B lineage ALL (Liu et al., 2014).